Is Vertex Pharmaceuticals Stock a Buy?
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.
Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two recent new drug approvals by the FDA, alongside several upcoming milestones in its extensive clinical pipeline portfolio.
Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
374,35 €
-0,60 %
Klare Kaufstimmung: Vertex Pharmaceuticals Inc. hat 47 Buy-Einschätzungen und keine Sell-Einschätzung.
Die Community erwartet für Vertex Pharmaceuticals Inc. ein Kursziel von 461 €, was eine Steigerung von über 20% gegenüber 374.35 € bedeuten würde.
